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Abstract
Background: TRIM5a and TRIMCyp are cytoplasmic proteins that bind incoming retroviral capsids and mediate
early blocks to viral infection. TRIM5 proteins form cytoplasmic bodies, which are highly dynamic structures. So far,
TRIM5 proteins have been found only in the cytoplasm of cells. Interestingly, other proteins from the TRIM family
localize to the nucleus. Therefore, we tested the possibility that TRIM5 proteins traffic to the nucleus and the
impact of this trafficking on retroviral restriction.
Results: Here we report that the TRIM5a proteins of two Old World primates, humans and rhesus monkeys, are
transported into the nucleus and are shuttled back to the cytoplasm by a leptomycin B-sensitive mechanism. In
leptomycin B-treated cells, these TRIM5a proteins formed nuclear bodies that also contained TRIM19 (PML).
Deletion of the amino terminus, including the linker 1 (L1) region, resulted in TRIM5a proteins that accumulated in
nuclear bodies. Leptomycin B treatment of TRIM5a-expressing target cells only minimally affected the restriction of
retrovirus infection.
Conclusions: We discovered the ability of human and rhesus TRIM5a to shuttle into and out of the nucleus. This
novel trafficking ability of TRIM5a proteins could be important for an as-yet-unknown function of TRIM5a.
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Background
Proteins of the tripartite motif (TRIM) family contain
RING, B-Box and coiled-coil domains, and thus have
been referred to as RBCC proteins [1]. Members of this
family have been implicated in diverse processes such as
cell proliferation, differentiation, development, oncogen-
esis and apoptosis [1,2]. TRIM proteins often self-associ-
ate and, when overexpressed, aggregate to form nuclear
or cytoplasmic bodies [1].
TRIM5a is a cytoplasmic protein that is capable of
restricting retrovirus infection in a species-dependent
manner [3]. Variation among TRIM5a proteins in dif-
ferent primates accounts for the early, post-entry blocks
to infection by particular retroviruses [3-7]. For exam-
ple, TRIM5a proteins of Old World monkeys block
human immunodeficiency virus (HIV-1) infection
[3-5,7], whereas TRIM5a proteins of New World
monkeys block infection by simian immunodeficiency
virus (SIVmac)[ 8 ] .T R I M 5 a from humans (TRIM5ahu)
is not as potent in restricting HIV-1 infection as Old
World monkey TRIM5a,b u tT R I M 5 ahu potently
restricts other retroviruses, e.g., N-tropic murine leuke-
mia virus (N-MLV) and equine infectious anemia virus
(EIAV) [3,4,6-8]. Owl monkeys, a New World monkey
species, are unusual in not expressing a TRIM5a pro-
tein, but instead express TRIMCyp, in which the RBCC
domains of TRIM5 are fused to a cyclophilin A moiety
[9,10].
Variation in splicing of the TRIM5 primary transcript
leads to the expression of TRIM5 isoforms, designated
a, g and δ [1]. The TRIM5a isoform contains, in addi-
tion to the RING, B-box 2 and coiled-coil domains, a
carboxy-terminal B30.2(SPRY) domain. The B30.2
(SPRY) domain is essential for the antiretroviral activity
of TRIM5a [3]. In some cases, the differences in the
ability of TRIM5a proteins from various primate species
to restrict particular retroviruses are determined by
sequences in the B30.2(SPRY) domain [11-19]. The
B30.2(SPRY) domain in TRIM5a and the cyclophilin A
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bind specifically to particular retroviral capsids
[9,20-24]. Additional sequences in the B-box 2 domain
contribute to higher-order self-association of TRIM5a,
which allows higher avidity for the retroviral capsid
[25-27]. TRIM5a proteins aggregate on the incoming
retroviral capsid [28]; and, by as-yet-uncertain mechan-
isms, decrease the stability of the capsid [23,27,29,30].
Some TRIM proteins localize in the nucleus of cells.
One example is TRIM19 (promyelocytic leukemia
(PML) protein), which is a major component of nuclear
domain 10 (ND10) bodies [31-33]. TRIM19 has been
shown to interfere with the replication of several DNA
and RNA viruses [34-41]. Both TRIM19 and TRIM5a
can inhibit herpes simplex virus replication [34,40,41],
and both proteins are induced by type I interferons
[18,42,43]. Thus, both cytoplasmic (e.g., TRIM5a)a n d
nuclear (e.g., TRIM19) TRIM proteins may be involved
in innate resistance to viral infection.
Here we study the intracellular localization of differ-
ent TRIM5a proteins and TRIMCyp after treatment of
cells with leptomycin B. Leptomycin B is a specific inhi-
bitor of the nuclear export factor CRM1 (exportin 1),
which is critical for the export of proteins carrying a
nuclear export sequence [44-49]. We document that
TRIM5ahu and TRIM5arh are actively shuttling between
the cytoplasm and nucleus. By contrast, TRIM5a pro-
teins from the squirrel monkey (a New World monkey)
and the cow did not accumulate in the nucleus upon
leptomycin B treatment. TRIMCyp from owl monkeys
also localized in the cytoplasm upon treatment with lep-
tomycin B. We investigated the contribution of the
nuclear export of TRIM5a to the antiretroviral activity
of the protein.
Results
Leptomycin B treatment results in nuclear accumulation
of some TRIM5a proteins
During the course of studying TRIM5a,w et e s t e dt h e
effect of leptomycin B (LMB), a specific inhibitor of
nuclear export [44-49], on TRIM5a localization. As
dogs do not express a functional TRIM5 protein[14], we
initially studied the localization of different TRIM5a
variants in canine cells. LMB treatment of Cf2Th canine
cells stably expressing TRIM5ahu or TRIM5arh resulted
in the accumulation of these proteins in the nucleus
(Figure 1). Both proteins were found in nuclear bodies
after LMB treatment. By contrast, TRIMCyp and the
TRIM5a proteins from cows and several species of New
World monkeys (squirrel monkeys, spider monkeys,
marmosets and tamarins) remained localized in the
cytoplasm after LMB treatment. These results suggest
that TRIM5ahu and TRIM5arh shuttle into the nucleus
and require active transport via the CRM1 protein to
achieve cytoplasmic localization.
Rapid accumulation of TRIM5ahu and TRIM5arh in the
nucleus after LMB treatment
To understand the kinetics of TRIM5arh movement into
the nucleus, we performed time-lapse fluorescent micro-
s c o p yu s i n gaH e L ac e l ll i n es t a b l ye x p r e s s i n gaT R I -
M5arh-yellow fluorescent protein (YFP) fusion. These
experiments revealed that treatment of cells with LMB
resulted in a rapid accumulation of TRIM5arh-GFP in
the nucleus (Figure 2). Nuclear bodies containing TRI-
M5arh-GFP were evident by 2 hours following the
initiation of LMB treatment.
Nuclear TRIM5ahu and TRIM5arh proteins localize to ND10
bodies with TRIM19
To examine whether TRIM5arh localizes to the same
ND10 bodies as TRIM19 after LMB treatment, LMB-
treated human cells stably expressing TRIM5arh were
stained with antibodies directed against TRIM19 and
the hemagglutinin (HA) epitope tag on TRIM5arh.T h e
nuclear TRIM5arh colocalized with TRIM19 (Figure
3A). Gold-labeled antibodies directed against the HA
epitope tag on TRIM5arh were used to investigate the
structure of the nuclear bodies. The TRIM5a-directed
antibodies formed ring-like structures similar in appear-
ance to those previously described for TRIM19 in ND10
bodies (Figure 3B) [31,33].
Localization of a TRIM5arh-pyruvate kinase fusion protein
The diameter of the nuclear pore is approximately 0.9
nm, which allows globular proteins less than 60 kD to
diffuse freely through the channel [50-52]. TRIM5a pro-
teins (approximately 55 kD) are close to this diffusion
limit. Moreover, TRIM5a forms a stable dimer [20,21];
however, we do not know if the majority of TRIM5a
molecules that enter the nucleus are monomers or
dimers. In addition, the molecular shape of TRIM5a is
unknown. These uncertainties raised the possibility that
TRIM5a is actively transported into the nucleus. To test
this possibility, TRIM5arh was fused to pyruvate kinase
(PK), which is normally a cytoplasmic protein [53] and
to the green fluorescent protein (GFP) to create the
GFP-PK-TRIM5arh chimeric protein. The GFP-PK-TRI-
M5arh protein and a control GFP-PK protein were tran-
siently expressed in HeLa cells (Figure 4). Localization
of these proteins was examined in untreated and LMB-
treated cells (Figure 4). After a two-hour treatment with
10 nM LMB, the GFP-PK-TRIM5arh protein was
detected in both the nucleus and the cytoplasm. By con-
trast, the GFP-PK protein was detected only in the cyto-
plasm of untreated and LMB-treated cells. These results
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the nucleus.
Identification of TRIM5arh regions modulating localization
Proteins that localize to the nucleus and shuttle to the
cytoplasm often contain nuclear localization and nuclear
export signals, respectively [44-48]. TRIM5ahu and TRI-
M5arh lack an obvious nuclear localization signal
[54,55], nor do they contain sequences motifs predicted
to function as nuclear export signals [56]. To gain some
insight into the TRIM5arh sequences that modulate
nuclear localization and export, a series of TRIM5arh
mutants with deletions in N-terminal components were
studied. The TRIM5arh Δ12 and TRIM5a Δ60 proteins
behaved like wild-type TRIM5arh with respect to locali-
zation in untreated cells (Figure 5A and Table 1). How-
ever, in the LMB-treated cells, TRIM5arh Δ12 and
TRIM5a Δ60 exhibited a bright, more diffuse pattern
with fewer nuclear bodies when compared with wild-
type TRIM5arh ( F i g u r e5 Aa n dT a b l e1 ) .T h e s er e s u l t s
indicate that neither the immediate TRIM5arh N-termi-
nus nor the RING domain significantly influence
nuclear localization and export. By contrast, the TRI-
M5arh Δ93 mutant localized to nuclear bodies and to
the cytosol, even in the absence of LMB treatment (Fig-
ure 5B and Table 1). This localization pattern did not
change significantly upon LMB treatment. Thus, dele-
tion of TRIM5arh sequences between residues 60 and
93, in the Linker 1 (L1) region of the protein, appears
to decrease the efficiency of nuclear export of
TRIM5arh.
Contribution of nuclear export of TRIM5ahu and TRIM5arh
to retroviral restriction
To study the contribution of TRIM5a nuclear export to
retroviral restriction, we treated cells stably expressing
TRIM5arh and TRIM5ahu with LMB for two hours.
Then the cells were challenged with recombinant HIV-1
and N-MLV expressing GFP. Treatment with LMB con-
tinued during the incubation of the cells with virus and
Figure 1 Retention of some TRIM5 variants in the nucleus after leptomycin B treatment. Cf2Th cells stably expressing the indicated HA-
tagged TRIM5a proteins were treated with 5 ng/ml of leptomycin B (LMB) or DMSO for two hours. Treated cells were stained using anti-HA
antibodies conjugated to FITC. Representative figures are shown.
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mal effects on the ability of TRIM5arh to restrict HIV-1
infection and on the ability of TRIM5ahu to inhibit N-
MLV infection (Figure 6).
Discussion
All characterized TRIM5a proteins are located in the
cytoplasm of expressing cells [15,28,57-59]. Here we
report the surprising observation that some TRIM5a
proteins are imported into the nucleus and then
exported back into the cytoplasm by a CRM1-dependent
mechanism. Of interest, this transient routing through
the nucleus was observed for the TRIM5a proteins of
two Old World primates, and not for the TRIM5a pro-
teins of a cow or several New World monkeys, or for
the TRIMCyp protein of another New World monkey
(the owl monkey). This raises the possibility that nuclear
shuttling represents a property that was gained by Old
World primate TRIM5a proteins after the divergence
from the New World monkeys.
Our results with the GFP-PK-TRIM5arh fusion pro-
t e i ns u g g e s tt h a tT R I M 5 arh is actively transported into
the nucleus, as the fusion protein is well above the size
limit for passive diffusion of proteins through the
nuclear pore [50-52]. Nonetheless, no typical nuclear
localization motif is evident on TRIM5a [54,55]. The
accumulation of TRIM5ahu and TRIM5arh in the
nucleus after LMB treatment implicates a CRM1-depen-
dent process in the export of these TRIM5a proteins
from the nucleus [44-49]. However, there are no classi-
cal nuclear export motifs in TRIM5a proteins [56]. It is
possible that TRIM5a utilizes unusual motifs for inter-
acting with nuclear pore proteins. Analysis of the locali-
zation of N-terminally truncated TRIM5arh mutants
suggests that deletion of residues 60-93, in the linker 1
(L1) region, disrupts the nuclear export of the protein.
Whether this is a result of deletion of a non-canonical
nuclear export signal or an indirect effect requires
further investigation. As an example of the latter effect,
the linker 1 (L1) regions could mediate the association
Figure 2 Time course of accumulation of YFP-TRIM5arh fusion protein in the nucleus after leptomycin B treatment. HeLa cells stably
expressing a YFP-TRIM5arh fusion protein were treated with 5 ng/ml of LMB or DMSO for 2 and 12 hours. Treated cells were stained using anti-
HA antibodies conjugated to FITC (green) and DAPI to stain the cell nucleus (blue). Representative figures are shown.
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shuttles between the nuclear and cytoplasm.
Despite the accumulation of TRIM5ahu and TRI-
M5arh proteins in the nucleus after LMB treatment,
restriction of N-MLV and HIV-1, respectively, remained
potent. Although it is possible that nuclear TRIM5ahu
and TRIM5arh can inhibit retrovirus infection, the spe-
cific recognition of the retroviral capsid, which does not
enter the intact nucleus, is thought to be important for
potent restriction [22,23]. A more likely explanation is
Figure 3 Colocalization of TRIM5a and TRIM19 (PML) in leptomycin B-treated cells. HeLa cells stably expressing HA-tagged TRIM5arh
proteins were treated with 5 ng/ml of leptomycin B (LMB) for two hours. Cells were stained for TRIM5a using anti-HA FITC-conjugated
antibodies. PML was stained using anti-PML antibodies and Cy3-conjugated anti-goat secondary antibodies (A). LMB-treated HeLa cells
expressing TRIM5arh were fixed. Ultrathin sections were labeled using an anti-HA antibody and Protein A-gold (10-nm particles). Ring-like
structures (n, nuclear bodies) in the cell nucleus were labeled with the antibody (B).
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Page 5 of 11Figure 4 Localization of a GFP-PK-TRIM5a p r o t e i ni nl e p t o m y c i nB - t r e a t e dc e l l s . HeLa cells transiently expressing the fusion constructs
GFP-PK or GFP-PK-TRIM5arh were treated with 5 ng/ml of LMB or with the equivalent concentration of DMSO for 2 hours (A). Protein expression
levels of the different fusion constructs were measured by Western blot using anti-GFP antibodies (B).
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Page 6 of 11Figure 5 Localization of TRIM5arh N-terminal deletion mutants in leptomycin B-treated cells. Cf2Th cells stably expressing wild-type
TRIM5arh or the indicated deletion mutant were treated with 5 ng/ml of LMB or DMSO for two hours. Treated cells were stained using anti-HA
antibodies conjugated to FITC. TRIM5arh domains are depicted for each variant, and the numbers of the amino acid residues at the boundaries
of the different domains are shown (A). L1 represents the Linker 1 region. The TRIM5arhΔ93 protein bodies are located in the cellular nucleus (B).
Cf2Th cells expressing TRIM5arhΔ93 were stained using using anti-HA antibodies conjugated to FITC (green) and propidium iodide for nuclear
staining (red). A representative image is shown.
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these overexpressing cells is sufficient to inhibit virus
infection. Any newly synthesized TRIM5a in these cells
that has not yet entered the nucleus is potentially avail-
able for capsid interaction.
One caveat of these studies is the use of exogenously
expressed TRIM5a proteins to study nuclear shuttling.
When better antibodies against endogenous TRIM5a
become available, the shuttling behavior of the endogen-
ously expressed TRIM5a protein can be examined.
What might be the possible advantage of having the
Old World primate TRIM5a proteins shuttle into and
out of the nucleus? If these TRIM5a proteins acquire
post-translational modifications or binding partners in
the process, our results suggest that such acquisition is
apparently not necessary for HIV-1 or N-MLV restric-
tion. The presence of TRIM5a in the nucleus could be
important for other TRIM5a functions besides retroviral
restriction. For example, Old World monkey TRIM5a
proteins have recently been shown to inhibit the infec-
tion of herpes simplex viruses 1 and 2 [41]. The coloca-
lization of nuclear TRIM5a in ND10 bodies with
TRIM19, which also has anti-herpes virus activity
[34,39,40], might have functional importance in this
respect. Future studies should shed light on these inter-
esting possibilities.
Conclusions
Here we discovered the ability of human and rhesus
TRIM5a to shuttle into and out of the nucleus.
Although not essential for retroviral restriction, this
novel ability of TRIM5a might be involved in other
functions such as the ability of TRIM5 to trigger NF-kB
[38].
Methods
Plasmid construction
The plasmids used to establish cell lines stably expres-
sing TRIM5a variants or TRIMCyp have been pre-
viously described [8,58]. The plasmids expressing
mutant TRIM5arh proteins with N-terminal deletions
were constructed by polymerase chain reaction (PCR)
amplification of TRIM5 cDNA, as previously described
[3]. The amplified fragments were cloned into the EcoRI
and Cla I sites of the pLPCX plasmid (Stratagene). All
of the TRIM5a proteins have an epitope tag from influ-
enza hemagglutinin (HA). Human TRIM5a has the HA
tag at the carboxyl terminus, and all the other TRIM5a
proteins have the HA tag at the amino terminus.
Creation of cells stably expressing TRIM5a and TRIMCyp
variants
Retroviral vectors encoding TRIM5a or TRIMCyp pro-
teins were created using the pLPCX vector plasmid [3].
Recombinant viruses were produced in 293T cells by
cotransfecting the pLPCX plasmids with the pVPack-GP
and pVPack-VSV-G packaging plasmids (Stratagene).
The pVPack-VSV-G plasmid encodes the vesicular sto-
matitis virus (VSV) G envelope glycoprotein, which
allows efficient entry into a wide range of vertebrate
cells.
Protein analysis
Cellular proteins were extracted with radioimmunopre-
cipitation assay (RIPA) buffer (10 mM Tris, pH 7.4; 100
mM NaCl; 1% sodium deoxycholate; 0.1% sodium dode-
cyl sulfate [SDS]; 1% NP-40; 2 mg of aprotinin/ml; 2 mg
of leupeptin/ml; 1 mg of pepstatin A/ml; 100 mg of phe-
nylmethylsulfonyl fluoride/ml). The cell lysates were
analyzed by SDS-PAGE (10% acrylamide), followed by
blotting onto nitrocellulose membranes (Amersham
Pharmacia Biotech). Detection of protein by Western
blotting utilized monoclonal antibodies that are specifi-
cally reactive with the HA epitope tag (Roche). Detec-
tion of proteins was performed by enhanced
chemiluminescence (NEN Life Sciences Products).
Infection with recombinant viruses expressing green
fluorescent protein (GFP)
Recombinant HIV-1 or N-MLV expressing GFP were
prepared as described [3]. HIV-1 viral stocks were quan-
tified by measuring reverse transcriptase (RT) activity.
For infections, 3 × 10
4 HeLa human epithelial cells or
Cf2Th canine cells seeded in 24-well plates were incu-
bated in the presence of virus for 24 hours. Cells were
washed and returned to culture for 48 hours, and then
Table 1 Number of TRIM5a cytoplasmic and nuclear bodies in LMB-treated cells
Number of cytoplasmic and nuclear bodies per 100 cells
DMSO LMB
Cytoplasmic Nuclear Total Cytoplasmic Nuclear Total
TRIM5arh 448 2 450 7 543 550
TRIM5arhΔ12 127 3 130* 5 128 133*
TRIM5arhΔ60 202 8 210* 2 78 80*
TRIM5arhΔ93 4 151 155 12 158 170
*Cytoplasmic and nuclear bodies of TRIM5arhΔ12 and Δ60 were on average larger than bodies observed for wt TRIM5arh and TRIM5arhΔ93 proteins.
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Page 8 of 11Figure 6 Effect of leptomycin B treatment of TRIM5a-expressing cells on retrovirus restriction. Cf2Th cells stably expressing TRIM5arh or
transduced with the empty vector LPCX were challenged with increasing amounts of HIV-1-GFP in the presence of 5 ng/ml of LMB or DMSO
(A). Similarly, Cf2Th cells stably expressing TRIM5ahu were challenged with increasing amounts of N-MLV-GFP in the presence of 5 ng/ml of LMB
or DMSO (B). TE671 cells, which naturally express TRIM5ahu, were challenged with B-MLV-GFP and N-MLV-GFP in the presence of the indicated
concentration of LMB or the DMSO control (C). The x-axis indicates the volume of a stock of recombinant GFP-expressing virus added to the
target cells. Forty-eight hours after infection, the percentage of infected cells was measured by counting the GFP-positive cells using a flow
cytometer. Similar results were obtained in three independent experiments.
Diaz-Griffero et al. Retrovirology 2011, 8:38
http://www.retrovirology.com/content/8/1/38
Page 9 of 11subjected to FACS analysis with a FACScan (Becton
Dickinson).
Intracellular location of TRIM5 variants
Localization of TRIM5 variants was studied as pre-
viously described [60]. Briefly, cells were grown over-
night on 12-mm-diameter coverslips and fixed in 3.9%
paraformaldehyde (Sigma) in phosphate-buffered saline
(PBS; Cellgro) for 30 minutes. In some experiments,
cells were incubated with 5 ng/ml leptomycin B (LMB)
in medium for 2-10 hours prior to fixation. Cells were
washed in PBS, incubated in 0.1 M glycine (Sigma) for
10 minutes, washed in PBS, and permeabilized with
0.05% saponin (Sigma) for 30 minutes. Samples were
blocked with 10% donkey serum (Dako, Carpinteria,
CA) for 30 minutes, and incubated for 1 hour with anti-
bodies. HA-tagged proteins were stained using an anti-
HA FITC-conjugated antibody, clone 3F10 (Roche). The
TRIM19 (PML) protein was stained with an antibody
against PML, sc-9863 (Santa Cruz Biotechnology, CA)
and anti-goat Cy3-conjugated antibodies(Jackson Immu-
noResearch, PA). Subsequently, samples were mounted
for fluorescence microscopy by using the ProLong Anti-
fade Kit (Molecular Probes, Eugene, OR). Images were
obtained with a BioRad Radiance 2000 laser scanning
confocal microscope with Nikon 60X N.A.1.4 optics.
Detection of TRIM5a by electron microscopy
HeLa cells stably expressing HA-tagged TRIM5arh trea-
t e dw i t h5n g / m lL M Bf o r2hw e r er e m o v e df r o mt h e
tissue culture dish with 5 mM EDTA in PBS, pelleted,
and resuspended in a small volume of 4% paraformalde-
hyde in 0.2 M sodium phosphate buffer, pH 7.4. Ultra-
thin sections were cut at -120˚C with a cryo-diamond
knife. Sections were picked up from the knife with a
loop dipped in a 1:1 mixture of 2.3 M sucrose and 2%
methylcellulose and transferred to a carbon-coated cop-
per grid. Grids were left floating on PBS with the sec-
tion facing down. Grids were washed in PBS and
blocked in 1% bovine serum albumin (BSA) in PBS for
15 min. Grids were then incubated with the anti-HA
3F10 antibody (Roche) in 1% BSA in PBS for 30 min
and washed four times for 15 min in PBS. Then, the
grids were incubated with Protein A-gold 10-nm parti-
cles (Jackson Immunoresearch) in 1% BSA in PBS for 20
min and washed four times for 15 min in PBS. Images
were acquired using a transmission electron microscope
JEOL 1200EX-80kV.
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